- Home
- DOCU vs ASND Comparison
DOCU vs ASND Comparison
Compare DOCU & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCU | ASND |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 13.6B |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DOCU | ASND |
|---|---|---|
| Price | $45.33 | $232.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 15 |
| Target Price | $81.00 | ★ $277.13 |
| AVG Volume (30 Days) | ★ 4.9M | 694.9K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1311.11 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $2,976,739,000.00 | N/A |
| Revenue This Year | $10.02 | $98.99 |
| Revenue Next Year | $6.69 | $41.45 |
| P/E Ratio | $43.93 | ★ N/A |
| Revenue Growth | ★ 7.78 | N/A |
| 52 Week Low | $40.16 | $124.06 |
| 52 Week High | $94.67 | $242.00 |
Technical Indicators
Market Signals| Indicator | DOCU | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 38.85 | 57.40 |
| Support Level | $41.53 | $190.49 |
| Resistance Level | $71.47 | $242.00 |
| Average True Range (ATR) | 2.21 | 9.59 |
| MACD | 0.67 | 0.44 |
| Stochastic Oscillator | 58.01 | 81.29 |
Price Performance
Historical ComparisonAbout DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.